Please assess the completion status of the following clinical trial:

Trial Title: Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients with clinical diagnosis of cyclic vomiting in the ED~Exclusion Criteria:~* pregnancy, allergy to any of the study medicines

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- haloperidol (Type: ACTIVE_COMPARATOR): these patients will receive 5mg IM haloperidol
- droperidol (Type: ACTIVE_COMPARATOR): these patients will receive 2.5mg IV droperidol
- ondansetron (Type: ACTIVE_COMPARATOR): these patients will receive 8mg IV ondansetron

Based on this trial design, predict the completion outcome and termination type (if applicable).